Literature DB >> 15000807

Serotoninergic polymorphisms (5-HTTLPR and 5-HT2A): association studies with psychosis in Alzheimer disease.

A Rocchi1, D Micheli, R Ceravolo, M L Manca, G Tognoni, G Siciliano, L Murri.   

Abstract

Patients with Alzheimer disease (AD) often exhibit psychotic symptoms associated with cognitive impairment. A few association studies have been carried out to determine if the serotonin transporter and receptor genes are potential risk factors for AD and/or associated psychopathology. The aim of this study was to investigate the association of a serotonin transporter gene-linked polymorphic region (5-HTTLPR) and the 5-HT2A receptor T102C polymorphism with the risk of developing dementia and/or psychotic symptoms in a group of sporadic AD patients from Italy. No significant differences in the distribution of allele and genotype frequencies of 5-HTTLPR and 5-HT2A T102C were found between patient and control groups. However, a significant association between the C102/C102 5-HT2A genotype and psychotic symptoms (p < 0.001) was observed. Our data strongly confirm results from previous studies suggesting that the C102 allele of the 5-HT2A receptor is associated with the occurrence of psychotic symptoms in AD. On the contrary, the serotonin transporter does not appear to be a major susceptibility factor in the pathophysiology of the disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15000807     DOI: 10.1089/109065703322783662

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  11 in total

1.  Localization of 5-HT1A and 5-HT2A positive cells in the brainstems of control age-matched and Alzheimer individuals.

Authors:  L Y Yeung; H F Kung; David T Yew
Journal:  Age (Dordr)       Date:  2010-05-28

Review 2.  Genetics of psychosis of Alzheimer disease.

Authors:  Chintan Shah; Mary Ann A DeMichele-Sweet; Robert A Sweet
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-01-12       Impact factor: 3.568

3.  Association study of polymorphisms in LRP1, tau and 5-HTT genes and Alzheimer's disease in a sample of Colombian patients.

Authors:  D A Forero; G Arboleda; J J Yunis; R Pardo; H Arboleda
Journal:  J Neural Transm (Vienna)       Date:  2005-12-14       Impact factor: 3.575

Review 4.  Psychiatric and behavioral symptoms in Alzheimer's disease and other dementias: etiology and management.

Authors:  Dag Aarsland; Sally Sharp; Clive Ballard
Journal:  Curr Neurol Neurosci Rep       Date:  2005-09       Impact factor: 5.081

Review 5.  Genetics of psychosis in Alzheimer's disease: a review.

Authors:  Mary Ann DeMichele-Sweet; Robert A Sweet
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 6.  Psychosis in Parkinson's Disease: A Lesson from Genetics.

Authors:  Efthalia Angelopoulou; Anastasia Bougea; Sokratis G Papageorgiou; Chiara Villa
Journal:  Genes (Basel)       Date:  2022-06-20       Impact factor: 4.141

7.  Prediction of psychosis onset in Alzheimer disease: the role of depression symptom severity and the HTR2A T102C polymorphism.

Authors:  Patricia A Wilkosz; Chowdari Kodavali; Elise A Weamer; Sachiko Miyahara; Oscar L Lopez; Vishwajit L Nimgaonkar; Steven T DeKosky; Robert A Sweet
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2007-12-05       Impact factor: 3.568

8.  Behavioural genetics of Alzheimer's disease: a comprehensive review.

Authors:  Marcin Flirski; Tomasz Sobow; Iwona Kloszewska
Journal:  Arch Med Sci       Date:  2011-05-17       Impact factor: 3.318

Review 9.  The Association between 5HT2A T102C and Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease: A Meta-Analysis.

Authors:  Liang Tang; Yan Wang; Yiwei Chen; Lianghui Chen; Shui Zheng; Meihua Bao; Ju Xiang; Huaiqing Luo; Jianming Li; Yungui Li
Journal:  Biomed Res Int       Date:  2017-11-16       Impact factor: 3.411

10.  The association of 5HT2A and 5HTTLPR polymorphisms with Alzheimer's disease susceptibility: a meta-analysis with 6945 subjects.

Authors:  Liang Tang; Jianming Li; Huaiqing Luo; Meihua Bao; Ju Xiang; Yiwei Chen; Yan Wang
Journal:  Oncotarget       Date:  2017-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.